Figure 5. Meta-analysis of the use of ACE inhibitors/ARBs on
the risk of COVID-19 related severe adverse clinical outcomes defined as
admission to the intensive care unit (ICU), the use of assisted
ventilation, or death (-26%,pooled OR=0.74, 0.56 to 0.99; p=0.04;
I2=78.5%).